05.09.18
Bristol-Myers Squibb
1Q Revenues: $5.2 billion (+5%)
1Q Earnings: $1.5 billion (-2%)
Comments: Eliquis sales were up 37% to $1.5 billion in the quarter. Opdivo sales were up 34% to $1.5 billion. Orencia sales were up 11% to $593 million. Sprycel sales were down 5% to $438 million. Yervoy sales were down 25% to $249 million. Established product sales were down including: Baraclude, down 20% to $225 million, the Sustiva Franchise, down 54% to $84 million, the Reyataz Franchise down 36% to $124 million, and the Hepatitis C Franchise, down 98% to $3 million.
1Q Revenues: $5.2 billion (+5%)
1Q Earnings: $1.5 billion (-2%)
Comments: Eliquis sales were up 37% to $1.5 billion in the quarter. Opdivo sales were up 34% to $1.5 billion. Orencia sales were up 11% to $593 million. Sprycel sales were down 5% to $438 million. Yervoy sales were down 25% to $249 million. Established product sales were down including: Baraclude, down 20% to $225 million, the Sustiva Franchise, down 54% to $84 million, the Reyataz Franchise down 36% to $124 million, and the Hepatitis C Franchise, down 98% to $3 million.
